Uncertainty around the event and suspected tax changes in the upcoming budget has left many investors in the dark.

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over its old heartburn drug Zantac, an issue that has weighed on the ...

Nodenza Venture Partners launchedFocus on international early-stage and pre-commercial biotech & medtech opportunitiesNew York, October 16, ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

Fortune noted that among the 55 women currently leading Fortune 500 companies, Barra is one of only nine who have been CEO ...

Stellantis CEO Carlos Tavares on Monday declined to rule out job cuts and said keeping up with Chinese competition and ...

British Prime Minister Keir Starmer kicked off an international business investment summit aimed at pulling in billions of ...

RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

Speculation is mounting GlaxoSmithKline's CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the dreaded activist investor Elliott Management built a stake in ...